XML 25 R13.htm IDEA: XBRL DOCUMENT v3.25.3
Concentration of Credit Risk and Current Expected Credit Losses
 9 Months Ended
Sep. 30, 2025
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk and Current Expected Credit Losses
Note 5. Concentration of Credit Risk and Current Expected Credit Losses
In November 2009, we entered into a collaboration and license agreement with Novartis Pharma AG (formerly known as Novartis Pharmaceutical International Ltd.) (“Novartis”). In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (“Lilly”). The above collaboration partners comprised, in aggregate, 20% and 19% of the accounts receivable balance as of September 30, 2025 and December 31, 2024, respectively. For further information relating to these collaboration and license agreements, refer to Note 8.
In November 2011, we began commercialization and distribution of JAKAFI and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of customers for these products. The concentration of credit risk related to our JAKAFI and OPZELURA product revenues is as follows:
Percentage of Total Net
Product Revenues for the
Three Months Ended		Percentage of Total Net
Product Revenues for the
Nine Months Ended
September 30,September 30,
2025202420252024
Customer A14 %15 %13 %15 %
Customer B8 %10 %9 %10 %
Customer C20 %20 %21 %19 %
Customer D15 %13 %15 %13 %
Customer E10 %10 %10 %10 %
Customer F11 %8 %10 %9 %
We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C, D, E and F comprised, in the aggregate, 59% and 54% of the accounts receivable balance as of September 30, 2025 and December 31, 2024, respectively. The concentration of credit risk relating to our other product revenues or accounts receivable is not significant.
We assessed our collaborative and customer receivable assets as of September 30, 2025 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. As of September 30, 2025 and December 31, 2024, we had no allowance for doubtful accounts.